Analyst Price Target is $58.89
▲ +22.25% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Inari Medical in the last 3 months. The average price target is $58.89, with a high forecast of $74.00 and a low forecast of $47.00. The average price target represents a 22.25% upside from the last price of $48.17.
Current Consensus is
Hold
The current consensus among 11 polled investment analysts is to hold stock in Inari Medical. This Hold consensus rating has held steady for over two years.
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Read More
